Swiss Severe Asthma Register

Inclusion criteria

• In- and outpatients • Age ≥ 0 year • Informed consent as documented by signature Adults: "Asthma which requires treatment with guidelines suggested medications for GINA steps 4-5 asthma: • High level therapy: 1. high dose ICS with ≥ 1000 μg beclomethasone (powder) or equivalent in combination with LABA or leukotriene modifier/theophylline) for the previous year or 2. Daily long-term therapy with systemic corticosteroids (CS) for ≥50% of the previous year to prevent it from becoming "uncontrolled" or which remains "uncontrolled" despite this therapy or 3. Therapy with monoclonal antibodies independent from the co-therapy • Middle level therapy: Protokollsynopsis SAR Version 01 16.01.2019 Seite 4/10 a) Daily long-term therapy with medium-to high-dose ICS (≥500 μg Beclomethason (powder) or equivalent in combination with LABA or leukotriene modifier/theophylline) for the previous year and uncontrolled asthma defined as at least one of the following: • Poor symptom control: ACQ consistently \>1.5, ACT \<20 (or "not well controlled" by NAEPP/GINA guidelines). • Frequent severe exacerbations: two or more bursts of systemic CS (\>3 days each) in the previous year. • Serious exacerbations: at least one hospitalization, ICU stay or mechanical ventilation in the previous year. • Airflow limitation: after appropriate bronchodilator withhold FEV1 \<80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal). • Controlled asthma that worsens on tapering of these high doses of ICS or systemic CS (or additional biologics). The presence of any one of the following exclusion criteria will lead to exclusion of the patients: • Life-expectancy \<6 months • Insufficient knowledge of project language Children: The criteria for severe or difficult asthma in children and adolescents are considered fulfilled in the case of insufficient symptom control in the last year despite medium/high antiinflammatory long-term therapy: • age 0-18 years, at time of inclusion • diagnosis of bronchial asthma made by a physician • differential diagnoses excluded • good compliance and trained inhalation technique • treatment with biological approved for the treatment of severe asthma (currently only omalizumab) or Proof of: a) Positive Bronchodilation-test (≥12% increase in FEV1 after SABA) or b) Significant bronchial hyperresponsiveness after nonspecific provocation (e.g., with Methacholine or treadmill) according to ATS criteria (AJRCCM 2000) • High level of therapy: 1. Prolonged therapy with high dose inhaled steroid (ICS) (\> 400 μg Budesonide equivalent /\> 200 μg fluticasone alone); or 2. Daily long-term therapy with medium- to high-dose ICS (≥ 400 μg Budesonide equivalent / ≥200 μg fluticasone) in combination with long-acting betaagonists and / or leukotriene receptor antagonist and / or theophylline; or 3. Therapy with oral steroids fixed ≥3 last months. • Insufficient asthma control a) Inadequate symptom control after NVL in the last 4 weeks: Protokollsynopsis SAR Version 01 16.01.2019 Seite 5/10 • ≥3 x weekly asthma symptoms or use of ondemand medication; Or: • limited activity due to asthma; Or: • any symptoms at night; or b. Exacerbation(s) ≥1 last year that required treatment with systemic steroids and / or inpatient treatment c. limited lung function: • pathological Tiffeneau quotient or FEV1 at inclusion. • Submission of a written consent (parent/ legal guardian).